Latest Breaking News On - Biomarin genzyme - Page 4 : vimarsana.com

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates - Full-year 2021 Financial Guidance Reaffirmed - Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan - Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec - FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results News provided by Share this article Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

United statesSanofi genzymeDebra charlesworthBiomarin novatoTraci mccartyJean jacques bienaimAllen instituteBiomarin pharmaceutical incReplay international numberCompany annual report on formBiomarin genzymeAllen institute collaborationCommittee for medicinal products human useDrug administrationEuropean commissionDevelopment expense